Cigna

Cigna Group shares declined 1.94% to close at $284.85, retreating from an intraday high of $293.01 reached early in the regular session, as the healthcare insurance sector faced renewed policy pressures and profit-taking momentum. The company declared a quarterly dividend and executed a 5-for-1 stock split on its Brazil BDR program, yet these corporate actions failed to provide sustained support. Q1 2026 fundamentals remain robust with earnings per share of $6.26, up 29% year-over-year, operating revenue of $68.49 billion (+4.57% YoY), and operating income of $3.75 billion (+57.32% YoY), supported by a ROE of 15.77%. Trading below its 20-day moving average of $286.86, the stock has retreated 9.71% from its 52-week high of $315.47, though it maintains a year-to-date gain of 2.05% from $279.12. The valuation appears reasonable at a P/E of 11.94 with a market cap near $75.1 billion, but sector headwinds and the post-market decline to $283.38 suggest investors are reassessing sentiment amid ongoing regulatory scrutiny in the pharmacy benefits sector.

Cigna Group rose 2.29% today, primarily driven by strong Q1 earnings results. The latest quarter delivered earnings per share of $6.26, representing a 29.07% year-over-year increase, with operating profit jumping 57.32% to $3.752 billion, while revenue grew to approximately $68.5 billion, up 4.57% year-over-year, demonstrating robust profitability momentum. In terms of intraday performance, pre-market gains of 1.08% were followed by regular session strength of 3.27%, with the stock closing near $290.49 before retreating 0.86% in post-market trading. From a valuation perspective, the current price-to-earnings ratio of 12.18x appears reasonable, with an annual dividend yield of 2.11%. However, the prior quarter's net profit declined 13.34% year-over-year, indicating seasonal variability in earnings.

Cigna rose 0.89% to $283.94 today, boosted by the Brazilian BDR stock split announcement and robust Q1 earnings, though wild pre-market swings suggest mixed market sentiment toward the news. Pre-market trading surged to $288.73 before sliding to $280.36—nearly a 3% range—then stabilized intraday near the session high. The 5-for-1 BDR split takes effect July 30 and triggered fragmented market reactions with mid-session selling pressure. Fundamentally, Q1 2026 delivered strong results: EPS of $6.26 (up 29% year-over-year), operating profit of $3.752 billion (up 57% year-over-year), and net profit up 25% year-over-year. Valuation remains attractive at 11.9x P/E, roughly 10% below the 52-week high of $315.47, while year-to-date gains are just 1.73%. Current price sits slightly below both 20-day and 60-day moving averages, reflecting cautious overall market positioning.

Cigna closed at $281.45, declining 0.84% from the previous close of $283.82 as profit-taking pressures offset early gains. The stock surged to an intraday high of $289.66 during the regular session before retreating, partly reflecting anticipation of the 5-for-1 BDR stock split in Brazil scheduled for July 30. Q1 2026 earnings revealed robust fundamentals: EPS climbed 29% year-over-year to $6.26, net income rose 25% to $1.654 billion, and revenue increased 4.57% to $68.49 billion, underscoring operational strength. However, regulatory headwinds persist as lawmakers intensify efforts to challenge insurance giants' dominance in the prescription drug sector. The stock trades 10.78% below its 52-week high of $315.47, well beneath the 20-day moving average of $286.12 and 60-day average of $285.88, with year-to-date gains of just 0.83%. The valuation sits at 11.8x P/E multiple.

CI.US declined 4.7% to $283.82 today, primarily driven by Brazil's announcement of a 5-for-1 stock split in the BDR program effective July 30. The stock initially surged to $306.30 in pre-market trading but subsequently retreated, touching an intraday low of $279.17 during regular hours before rebounding to $285.40 in post-market sessions. Q1 earnings showed EPS growth of 29% year-over-year to $6.26, operating profit surging 57% to $3.752 billion, and net margin expanding to 2.41%, signaling solid operational momentum. The 11.9x P/E valuation remains relatively modest. Year-to-date, the stock has gained 1.68%, though it trades 10% below its October 2025 peak of $315.47. However, congressional antitrust scrutiny targeting Cigna's dominance in the prescription drug market is intensifying, with the company facing business separation requirements across multiple states.